13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • INTEGRATE 2

    Acronym: 

    INTEGRATE 2

    ACTRN/NCT /ethics: 

    ACTRN12616000420448

    Scientific title: 

    A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

    Summary of trial and patient characteristics

    Cancer Type Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase III Tumour Stream Stomach, Oesophagus
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2016-07-01
    Molecular Target Anticipated End Date
    Cancer Type Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Stomach, Oesophagus
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2016-07-01
    Anticipated End Date

    Trial Summary

    The purpose of this phase III study is to determine whether regorafenib is effective in prolonging survival in patients with advanced gastro-oesophageal carcinoma.

    Lay Summary

    A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

    Sponsor / Cooperative group

    The Australasian Gastro-Intestinal Trials Group (AGITG)

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Chris Karapetis Recruiting
    The Queen Elizabeth Hospital Sue Yeend Sue.Yeend@sa.gov.au 08 8222 6148 Tim Price Recruiting